Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 78

1.

Advanced systemic mastocytosis with strong expression of signaling lymphocyte activation marker family member 7 (SLAMF7) responsive to therapy with elotuzumab and lenalidomide.

Elmaagacli AH, Jehn C, Shikova Y, Huber M, Salwender H, Dahmash F, Singh A, Niggemann C, Vierbuchen M.

Leuk Lymphoma. 2020 Feb;61(2):485-487. doi: 10.1080/10428194.2019.1668939. Epub 2019 Sep 30. No abstract available.

PMID:
31566043
2.

Strong expression of SLAMF7 in natural killer/T-cell lymphoma and large granular lymphocyte leukemia - a prominent biomarker and potential target for anti-SLAMF7 antibody therapy.

Elmaagacli AH, Salwender H, Jehn C, Dahmash F, Singh A, Wilson O, Pannenbeckers M, Niggemann C, Vierbuchen M.

Leuk Lymphoma. 2019 Dec;60(13):3335-3338. doi: 10.1080/10428194.2019.1623887. Epub 2019 Jun 4. No abstract available.

PMID:
31164030
3.

Cytomegalovirus induces HLA-class-II-restricted alloreactivity in an acute myeloid leukemia cell line.

Koldehoff M, Lindemann M, Ross SR, Elmaagacli AH.

PLoS One. 2018 Jan 29;13(1):e0191482. doi: 10.1371/journal.pone.0191482. eCollection 2018.

4.

Early CMV-replication after allogeneic stem cell transplantation is associated with a reduced relapse risk in lymphoma.

Koldehoff M, Ross SR, Dührsen U, Beelen DW, Elmaagacli AH.

Leuk Lymphoma. 2017 Apr;58(4):822-833. doi: 10.1080/10428194.2016.1217524. Epub 2016 Aug 10.

PMID:
27687578
5.

Cytomegalovirus replication reduces the relapse incidence in patients with acute myeloid leukemia.

Elmaagacli AH, Koldehoff M.

Blood. 2016 Jul 21;128(3):456-9. doi: 10.1182/blood-2016-04-713644. Epub 2016 May 23. No abstract available.

PMID:
27216219
6.

Cytomegalovirus induces apoptosis in acute leukemia cells as a virus-versus-leukemia function.

Koldehoff M, Lindemann M, Opalka B, Bauer S, Ross RS, Elmaagacli AH.

Leuk Lymphoma. 2015;56(11):3189-97. doi: 10.3109/10428194.2015.1032968. Epub 2015 May 15.

PMID:
25818505
7.

Inhibition of mTOR with everolimus and silencing by vascular endothelial cell growth factor-specific siRNA induces synergistic antitumor activity in multiple myeloma cells.

Koldehoff M, Beelen DW, Elmaagacli AH.

Cancer Gene Ther. 2014 Jul;21(7):275-82. doi: 10.1038/cgt.2014.27. Epub 2014 Jun 6.

PMID:
24903015
8.

Human chorionic gonadotropin and indolamine 2,3-dioxygenase in patients with GVHD.

Elmaagacli AH, Ditschkowski M, Steckel NK, Gromke T, Ottinger H, Hillen U, Baba HA, Trenschel R, Beelen DW, Koldehoff M.

Bone Marrow Transplant. 2014 Jun;49(6):800-5. doi: 10.1038/bmt.2014.59. Epub 2014 Mar 31.

PMID:
24686986
9.
10.

CMV and relapse: what has conditioning to do with it?

Elmaagacli AH.

Biol Blood Marrow Transplant. 2014 Jan;20(1):1-2. doi: 10.1016/j.bbmt.2013.11.004. Epub 2013 Nov 8. No abstract available.

11.

Maternal molecular features and gene profiling of monocytes during first trimester pregnancy.

Koldehoff M, Cierna B, Steckel NK, Beelen DW, Elmaagacli AH.

J Reprod Immunol. 2013 Sep;99(1-2):62-8. doi: 10.1016/j.jri.2013.07.001. Epub 2013 Aug 16.

PMID:
23958292
12.

Increased susceptibility for aspergillosis and post-transplant immune deficiency in patients with gene variants of TLR4 after stem cell transplantation.

Koldehoff M, Beelen DW, Elmaagacli AH.

Transpl Infect Dis. 2013 Oct;15(5):533-9. doi: 10.1111/tid.12115. Epub 2013 Jul 25.

PMID:
23890253
13.

Additive antileukemia effects by GFI1B- and BCR-ABL-specific siRNA in advanced phase chronic myeloid leukemic cells.

Koldehoff M, Zakrzewski JL, Beelen DW, Elmaagacli AH.

Cancer Gene Ther. 2013 Jul;20(7):421-7. doi: 10.1038/cgt.2013.31. Epub 2013 Jun 21.

PMID:
23788109
14.

Thoughts on feto-maternal tolerance: is there a lesson to be learned from allogeneic haematopoietic stem cell transplantation?

Koldehoff M, Elmaagacli AH.

Cell Biol Int. 2013 Aug;37(8):766-7. doi: 10.1002/cbin.10106. Epub 2013 Apr 18. No abstract available.

PMID:
23554022
15.

Bronchiolitis obliterans after allogeneic hematopoietic SCT: further insight--new perspectives?

Ditschkowski M, Elmaagacli AH, Koldehoff M, Gromke T, Trenschel R, Beelen DW.

Bone Marrow Transplant. 2013 Sep;48(9):1224-9. doi: 10.1038/bmt.2013.17. Epub 2013 Feb 25.

PMID:
23435515
16.

Delayed graft-versus-mast-cell effect on systemic mastocytosis with associated clonal haematological non-mast cell lineage disease after allogeneic transplantation.

Gromke T, Elmaagacli AH, Ditschkowski M, Hegerfeldt Y, Koldehoff M, Hlinka M, Ottinger H, Trenschel R, Beelen DW.

Bone Marrow Transplant. 2013 May;48(5):732-3. doi: 10.1038/bmt.2012.198. Epub 2012 Oct 22. No abstract available.

PMID:
23085825
17.

Dynamic International Prognostic Scoring System scores, pre-transplant therapy and chronic graft-versus-host disease determine outcome after allogeneic hematopoietic stem cell transplantation for myelofibrosis.

Ditschkowski M, Elmaagacli AH, Trenschel R, Gromke T, Steckel NK, Koldehoff M, Beelen DW.

Haematologica. 2012 Oct;97(10):1574-81. doi: 10.3324/haematol.2011.061168. Epub 2012 Apr 4.

18.

Modulating impact of human chorionic gonadotropin hormone on the maturation and function of hematopoietic cells.

Koldehoff M, Katzorke T, Wisbrun NC, Propping D, Wohlers S, Bielfeld P, Steckel NK, Beelen DW, Elmaagacli AH.

J Leukoc Biol. 2011 Nov;90(5):1017-26. doi: 10.1189/jlb.0910520. Epub 2011 Aug 30.

PMID:
21878542
19.

Clinical course and molecular features in 21 patients with atypical chronic myeloid leukemia.

Koldehoff M, Steckel NK, Hegerfeldt Y, Ditschkowski M, Beelen DW, Elmaagacli AH.

Int J Lab Hematol. 2012 Feb;34(1):e3-5. doi: 10.1111/j.1751-553X.2011.01351.x. Epub 2011 Jun 27. No abstract available.

PMID:
21707937
20.

Progressive improvement in cutaneous and extracutaneous chronic graft-versus-host disease after a 24-week course of extracorporeal photopheresis--results of a crossover randomized study.

Greinix HT, van Besien K, Elmaagacli AH, Hillen U, Grigg A, Knobler R, Parenti D, Reddy V, Theunissen K, Michallet M, Flowers ME; UVADEX Chronic GVHD Study Group.

Biol Blood Marrow Transplant. 2011 Dec;17(12):1775-82. doi: 10.1016/j.bbmt.2011.05.004. Epub 2011 May 11.

21.

Early human cytomegalovirus replication after transplantation is associated with a decreased relapse risk: evidence for a putative virus-versus-leukemia effect in acute myeloid leukemia patients.

Elmaagacli AH, Steckel NK, Koldehoff M, Hegerfeldt Y, Trenschel R, Ditschkowski M, Christoph S, Gromke T, Kordelas L, Ottinger HD, Ross RS, Horn PA, Schnittger S, Beelen DW.

Blood. 2011 Aug 4;118(5):1402-12. doi: 10.1182/blood-2010-08-304121. Epub 2011 May 3.

PMID:
21540462
22.

Toll-like receptor 9, NOD2 and IL23R gene polymorphisms influenced outcome in AML patients transplanted from HLA-identical sibling donors.

Elmaagacli AH, Steckel N, Ditschkowski M, Hegerfeldt Y, Ottinger H, Trenschel R, Koldehoff M, Beelen DW.

Bone Marrow Transplant. 2011 May;46(5):702-8. doi: 10.1038/bmt.2010.166. Epub 2010 Jul 12.

PMID:
20622911
23.

Retrospective analysis of treosulfan-based conditioning in comparison with standard conditioning in patients with myelodysplastic syndrome.

Hilgendorf I, Wolff D, Gromke T, Trenschel R, Elmaagacli AH, Pichlmeier U, Junghanss C, Freund M, Beelen DW, Casper J.

Bone Marrow Transplant. 2011 Apr;46(4):502-9. doi: 10.1038/bmt.2010.153. Epub 2010 Jun 28.

PMID:
20581886
24.

H1N1 in allogeneic stem cell recipients: courses of infection and influence of vaccination on graft-versus-host-disease (GVHD).

Ditschkowski M, Elmaagacli AH, Beelen DW.

Ann Hematol. 2011 Jan;90(1):117-8. doi: 10.1007/s00277-010-0971-8. Epub 2010 Apr 30. No abstract available.

PMID:
20432037
25.

No influence of gene polymorphism of LCT (C13910T) on transplantation outcomes in acute myeloid leukemia patients who received transplantations from HLA-identical sibling donors.

Elmaagacli AH, Steckel N, Ditschkowski M, Hegerfeldt Y, Ottinger H, Trenschel R, Beelen DW.

Blood. 2010 Apr 29;115(17):3644-5; author reply 3645-6. doi: 10.1182/blood-2010-02-267443. No abstract available.

PMID:
20430969
26.

Small interfering RNA against BCR-ABL transcripts sensitize mutated T315I cells to nilotinib.

Koldehoff M, Kordelas L, Beelen DW, Elmaagacli AH.

Haematologica. 2010 Mar;95(3):388-97. doi: 10.3324/haematol.2009.016063.

27.

Therapeutic targeting of gene expression by siRNAs directed against BCR-ABL transcripts in a patient with imatinib-resistant chronic myeloid leukemia.

Koldehoff M, Elmaagacli AH.

Methods Mol Biol. 2009;487:451-66. doi: 10.1007/978-1-60327-547-7_22.

PMID:
19301661
28.

Improved outcome of hematopoietic SCT in patients with homozygous gene variant of Toll-like receptor 9.

Elmaagacli AH, Koldehoff M, Beelen DW.

Bone Marrow Transplant. 2009 Sep;44(5):295-302. doi: 10.1038/bmt.2009.32. Epub 2009 Mar 2.

PMID:
19252531
29.

Small-molecule inhibition of proteasome and silencing by vascular endothelial cell growth factor-specific siRNA induce additive antitumor activity in multiple myeloma.

Koldehoff M, Beelen DW, Elmaagacli AH.

J Leukoc Biol. 2008 Aug;84(2):561-76. doi: 10.1189/jlb.0907632. Epub 2008 May 5.

PMID:
18458152
30.

Gene profiling of growth factor independence 1B gene (Gfi-1B) in leukemic cells.

Koldehoff M, Zakrzewski JL, Klein-Hitpass L, Beelen DW, Elmaagacli AH.

Int J Hematol. 2008 Jan;87(1):39-47. doi: 10.1007/s12185-007-0013-z. Epub 2007 Dec 6.

PMID:
18224412
31.

Relation of an interleukin-23 receptor gene polymorphism to graft-versus-host disease after hematopoietic-cell transplantation.

Elmaagacli AH, Koldehoff M, Landt O, Beelen DW.

Bone Marrow Transplant. 2008 May;41(9):821-6. doi: 10.1038/sj.bmt.1705980. Epub 2008 Jan 21.

PMID:
18209723
32.

Cytochrome P450 2C19 loss-of-function polymorphism is associated with an increased treatment-related mortality in patients undergoing allogeneic transplantation.

Elmaagacli AH, Koldehoff M, Steckel NK, Trenschel R, Ottinger H, Beelen DW.

Bone Marrow Transplant. 2007 Oct;40(7):659-64. Epub 2007 Aug 6.

PMID:
17680025
34.

Therapeutic application of small interfering RNA directed against bcr-abl transcripts to a patient with imatinib-resistant chronic myeloid leukaemia.

Koldehoff M, Steckel NK, Beelen DW, Elmaagacli AH.

Clin Exp Med. 2007 Jun;7(2):47-55. Epub 2007 Jul 4.

PMID:
17609876
36.
37.

No influence of V617F mutation in JAK2 on outcome after allogeneic hematopoietic stem cell transplantation (HSCT) for myelofibrosis.

Ditschkowski M, Elmaagacli AH, Trenschel R, Steckel NK, Koldehoff M, Beelen DW.

Biol Blood Marrow Transplant. 2006 Dec;12(12):1350-1. No abstract available.

38.

Donor cell reaction to OKT3 as predictor of chronic graft-vs-host disease in hematopoietic stem cell recipients.

Lindemann M, Ottinger HD, Elmaagacli AH, Trenschel R, Rebmann V, Beelen DW, Grosse-Wilde H.

Exp Hematol. 2006 Dec;34(12):1753-8.

PMID:
17157173
39.

Growth factor-independent 1B gene (GFI1B) is overexpressed in erythropoietic and megakaryocytic malignancies and increases their proliferation rate.

Elmaagacli AH, Koldehoff M, Zakrzewski JL, Steckel NK, Ottinger H, Beelen DW.

Br J Haematol. 2007 Jan;136(2):212-9. Epub 2006 Dec 8.

PMID:
17156408
41.

Myeloablative allogeneic hematopoietic stem cell transplantation in elderly patients.

Ditschkowski M, Elmaagacli AH, Trenschel R, Steckel NK, Koldehoff M, Beelen DW.

Clin Transplant. 2006 Jan-Feb;20(1):127-31.

PMID:
16556167
42.

Synthetic small interfering RNAs reduce bcr-abl gene expression in leukaemic cells of de novo Philadelphia(+) acute myeloid leukaemia.

Koldehoff M, Steckel NK, Beelen DW, Elmaagacli AH.

Clin Exp Med. 2006 Mar;6(1):45-7. No abstract available.

PMID:
16550344
43.

Mutations in innate immune system NOD2/CARD 15 and TLR-4 (Thr399Ile) genes influence the risk for severe acute graft-versus-host disease in patients who underwent an allogeneic transplantation.

Elmaagacli AH, Koldehoff M, Hindahl H, Steckel NK, Trenschel R, Peceny R, Ottinger H, Rath PM, Ross RS, Roggendorf M, Grosse-Wilde H, Beelen DW.

Transplantation. 2006 Jan 27;81(2):247-54.

PMID:
16436969
44.

Successful treatment of patients with respiratory failure due to fungal infection after allogeneic hematopoietic stem cell transplantation.

Koldehoff M, Elmaagacli AH, Steckel NK, Trenschel R, Hlinka M, Ditschkowski M, Beelen DW.

Transpl Infect Dis. 2005 Sep-Dec;7(3-4):137-45.

PMID:
16390403
45.

Reduced risk for molecular disease in patients with chronic myeloid leukemia after transplantation from a KIR-mismatched donor.

Elmaagacli AH, Ottinger H, Koldehoff M, Peceny R, Steckel NK, Trenschel R, Biersack H, Grosse-Wilde H, Beelen DW.

Transplantation. 2005 Jun 27;79(12):1741-7.

PMID:
15973179
46.

Caspofungin as second-line therapy for fever of unknown origin or invasive fungal infection following allogeneic stem cell transplantation.

Trenschel R, Ditschkowski M, Elmaagacli AH, Koldehoff M, Ottinger H, Steckel N, Hlinka M, Peceny R, Rath PM, Dermoumi H, Beelen DW.

Bone Marrow Transplant. 2005 Mar;35(6):583-6.

PMID:
15756283
47.

WT1 and BCR-ABL specific small interfering RNA have additive effects in the induction of apoptosis in leukemic cells.

Elmaagacli AH, Koldehoff M, Peceny R, Klein-Hitpass L, Ottinger H, Beelen DW, Opalka B.

Haematologica. 2005 Mar;90(3):326-34.

48.

Indoleamine 2,3-dioxygenase expression in monocytes of healthy nonpregnant women after induction with human choriongonadotropine.

Steckel NK, Koldehoff M, Beelen DW, Elmaagacli AH.

Scand J Immunol. 2005 Feb;61(2):213-4. No abstract available.

49.
50.

Outcome of hematopoietic stem cell transplantation in patients with atypical chronic myeloid leukemia.

Koldehoff M, Beelen DW, Trenschel R, Steckel NK, Peceny R, Ditschkowski M, Ottinger H, Elmaagacli AH.

Bone Marrow Transplant. 2004 Dec;34(12):1047-50.

PMID:
15516946

Supplemental Content

Loading ...
Support Center